PEOPLE - Genzyme makes appointment:
This article was originally published in Clinica
Executive Summary
David McLachlan is to retire as chief financial officer of US biotechnology company Genzyme on June 1. He will be succeeded by Michael Wyzga, senior vice-president, corporate controller and chief accounting officer. Mr McLachlan will remain as part-time advisor to the company on strategic financial issues.